and good Chuck, everyone. you, Thank morning,
our combination, in meet my to the Pfizer latest business care following performance, our which expect completion to plans During discuss updates the of we for I anticipated remarks, continue Upjohn-Mylan quarterly pipeline will XXXX. from and our
the During in performance by of anticipate closing business growth X% transaction. delivered revenue the following be the that operational Biopharmaceuticals will strong quarter, the we Upjohn which Pfizer at remains Pfizer highlighted our a Group,
with Consumer expected joint also exclusivity July the impacted the revenue completion by events, saw GSK. the the two and of U.S. July in loss transaction for We venture Lyrica XX of Healthcare
well growth growth XX% XX% biopharmaceuticals, This including our as by key Vyndaqel operational For include Eliquis, markets was growth growth China. emerging operational Ibrance, groups again, as once strong these Inlyta, outstanding end drivers. primarily in driven performance from in Xtandi, Xeljanz,
the business this than biopharmaceutical quarter the Upjohn Our China country. business in generated in revenues higher
quarter to and physicians the of markets. revenues XX% them had is in or who both a compared to continued quarter. strong revenue not specific target the small We was result international had patients. U.S. prescribing prescribed been of a only inhibitors business operationally set for operationally to year were our efforts U.S. CDK believe saw the billion. We Global particularly in strong oncology Ibrance Our $X.X growth up with in the XX% ago up growth
Xtandi, FDA represents alliance cancer revenues the U.S. men growth If for in another August, to date with the Xtandi get grew for prostate granted brand. review hormone driver of PDUFA the the this a designation XX% December. In in sensitive metastatic treatment approved, For potential priority with $XXX million. the
increased the Inlyta has XXX% carcinoma treatment in of combination cell and million. revenues This approvals to patients. Inlyta FDA operationally in KEYTRUDA the for Inlyta plus growth Inlyta XX% from renal $XXX included of or recent benefited plus U.S. BAVENCIO advanced first-line
were $XXX both strong the Oncology, markets several the had million. in Xeljanz XX% to contributed also operationally Global other arthritis for the ulcerative volume in arthritis and growth. indication. U.S. colitis for growth in Beyond we We to psoriatic launches other for certain saw significantly revenues up the and rheumatoid recent developed continued And product U.S. performances. the
perform Global oral growth driven XX% to in continued by continued as up market primarily $X well well. non-valvular revenues were was adoption fibrillation, also as operationally to atrial gains. Eliquis billion. share anti-coagulant This increased
launch. nicely ramp diseases following XXXX the U.S. May rare at Looking and Vyndaqel our the to approval up business, continues in
disease the have awareness X% efforts with than drive quarter greater to the in early to Our prior helped rates X% launch. compared diagnosis
program. approximately not X,XXX include approximately Vyndaqel do As early number approximately had for had diagnosed, patients This receive X,XXX drug. of the patients of could the prescription X,XXX end been received and the August, access patients
include increases to you number X,XXX. the receiving of drug patients the approximately If these,
which XX were and in ACIP’s vaccine older, the XX, down slightly is for adults U.S. until recommendation global the and revenues the publication Regarding to mortality We vaccine Phase both, investigational X the for safe completing considered and FDA effective pneumococcal the not reinforces for Prevnar that forward conjugate of look the our franchise. studies morbidity across XX-valent report, and the weekly is successfully by ACIP. Prevnar of XX candidate. updated effective
This increased candidate X% introducing injectables, revenues are X U.S. advancements taking revenues shape. increased serotypes serotypes. contained and a PCVXX manufacturing plus seeing Global compared X% recovery we In with by operationally additional potential operationally. a XX-valent represents all in sterile our significant potential focus on
to growth business this to We be expect contributor continue the in solid a future.
moving Revenues were declines significant the Now for by business our in that in let generic operationally Upjohn U.S. down me began Lyrica decline competition primarily the multi-source the was XXXX. in to expected to quarter. The July due Upjohn. volume XX% driven in
operationally. would decline X% Excluding have been the Lyrica impact, the only
increased cities. Upjohn’s the Despite program XX operationally. the in China volume based X% revenues procurement
our compared instead Given these, had digits grow we XXXX Consumer XX% GSK. low-to-mid by revenues in XXXX, operationally, call. with predicted expect digit XXXX now Upjohn’s mid-to-high reflecting year to we single Joint of million, full totaled the Venture previous of revenues with down quarter the single China full XX, July XXXX in Consumer $XXX year Healthcare, transaction the Healthcare earnings that completion third
milestones. concept of pipeline, positive Turning now opportunities XX-valent investigational pneumococcal our earnings media had X a preliminary breadth of conjugate vaccine are Phase depth invasive of with and disease XX, science. and In otitis vaccines, in the our healthy to from we of of R&D, Since terms with investigation study be making seen our announced exciting prevention both under results we some infants. proof for of last in on July continue we the we to the excited the call the progress
discuss with X dose to available, with we Phase intend the are data Once regulators. fourth plans
our adults, We disease vaccine our Phase prevention XX-valent also invasive the X clinical of evaluating years investigational and in have completed pneumonia for enrollment older. trials and XX pivotal three in
diseases, the we the in month, gene rare Pfizer severe This the the clinical X for manufacturing completed program. In A. hemophilia enrolled the first Phase transfer for of trial patient SB-XXX have from to lead-in Sangamo therapy we of the investigational processes
primary dosing global our XXXX. partner Somatrogon its met that begin once children XX, for dose in of growth hormone pre-pubertal weekly the patients with injectable expect We non-inferiority evaluating endpoint Pfizer of that half X to to October first daily announced trial Genotropin. the Phase with OPKO deficiency in jointly trial On
weekly results significant once to potential the offer benefits very because solution this pleased patients. may We are with
other are looking regulators. a forward presenting scientific data FDA We discussing the in to and and them conference detailed with
top Immunology, pivotal and line our addition in recently positive medical were evaluating These MONO-X. the inhibitor, atopic JADE to positive for results indication are This was announced findings Inflammation dermatitis. Phase where at month oral patients Phase from of with a earlier conference. study, safety Abrocitinib we moderate-to-severe JAKX In and this in the the Abrocitinib in X data this efficacy second with our study the first full X results presented
certain therapy hypertriglyceridemia diseases. Akcea help being The recently program therapy patients diabetes, and in reach antisense with patients a evaluated an Phase AKCEA-ANGPTLX-LRx, therapies and will disease. In our we entered internal X its Therapeutics Internal diseases X allow into We patients. being worldwide Medicine cardiovascular in pipeline to maximum medicine, metabolic for this currently complement cardiovascular exclusive to believe investigational treat liver fatty our type with novel with clinical licensing this potential agreement that a metabolic study deep for will expertise mid-stage and non-alcoholic and in developed
for of Lastly BRAFVXXXE-mutant Braftovi and we and from the FDA regarding this of BEACON supplementary presented submitted cetuximab objective as Array, survival combinations in recent review. announce to rates application acceptance with colorectal with drug acquisition our a Braftovi/Mektovi We new will user results from Oncology, significant response the And saw treatment cancer. for we their improvements the of X interim statistically per in versus patients trial metastatic decision data. Phase practice, overall analysis control. recently our
on XXXX. to And U.S. FDA. launch by approved on to Zirabev serve February have this three XXXX. pleased expected the for Trazimera what I now And our is am of of XX Ruxience year of December XXXX. January we days of launch biosimilars in recently XX
all the So future. near
improve course, them. at remains to and none both levels good both the with federal aisle policymakers on any patients working of common state solutions of patients do can’t sense Of patients’ affordability. on sides will our afford the committed breakthroughs and Pfizer to if
certain areas. We are progress making in
For have regarding issue been well and biosimilars received on bipartisan is legislation this example, proposals advancing. our
We and work seniors. reduce in pocket healthcare to find to policymakers at ways counter, system the to of pharmacy the for out costs also especially continue others with
value lawmakers that produce pocket an need for to outcomes the out the And Medicare of recognize to reimbursement ability pursuing for in positive our arrangements tie Part We particularly aggressively annual patients. based of are D. we medicines are encouraged cap that
has the that way but in discussion difficult around It’s of imagine American proposals. continued less explicitly developed lot solutions drive will medicines remain be life will Therefore, confident found, a to can patients. there constructive saving stand the that of innovation benefit being patients. been Congress common sense available While we supporting and to made policies and
who In excitement rely vaccines. continues a innovative for our hope shareholders and and and medicines quarter turn on of the company, our our summary, our in solid to patients and great be we source another pipeline
date, forward. our in to and for our guidance midpoints our well as reflect XXXX confidence as performance the strong also We diluted going business EPS raised to adjusted ranges revenue the
details a provide more Frank from in will moment. this
Following And transaction. the five-year on growth Pfizer the expect upon and company and our will remain pipeline for expected be singular close Upjohn-Mylan biopharma. close transaction next Pfizer growth we focus approximately with begin to this of smaller, innovative current will revenue X%, the drivers immediately that a with science-based be All for year, of reason. CAGR Pfizer’s the to
group growing is already bio-pharmaceuticals pace. similar Our a at
in-license second Therapeutics, pipeline These this the in strengthen continue currently represent will investigational agreements interest equity our the of expect mitigate acquisitions the therapy and types Therachon have we in to with we Therapeutics half to the BD compounds of and that the of but LOEs. the of will new of pursue set from LOEs, substrate the Array Starting impact a next for help wave XXXX, decade. Akcea we to the new Vivet of our initiatives help targeted in along
confidence and invest our ability growth are investors. to deliberate new while to in continue and commercialize our making in important are vaccines of the to These to we have medicines capital ability returning because moves science, in in we our
outlook over to on to the let Frank? and details provide me our turn Frank for Now, it remainder the of XXXX. quarter
